PharmaCyte Biotech Inc (PMCB)

[Edward]

Iroquois Capital is setting it up to stop operations and liquidate the company. Which they planed all along. The cash is worth close to $4 a share So with a liquidation shareholders will receive approx $3.25-3.75 per share.

After the review they will say continuing with clinical activities is not in the best of the stockholders, therefore PMCB will close and liquidate the company.

On October 7, 2022 Iroquios made the below statement:

"In addition, we are evaluating the concerns expressed by the U.S. Food and Drug Administration (FDA) with regard to the clinical hold placed on the IND for the Cell-in-a-Box(R) technology. Inclusive to our concerns over the FDA clinical hold is the exploration of the current relationship with SG Austria and determining whether the interests of SG Austria and those of PharmaCyte are appropriately aligned in order to continue to pursue the development of this technology under the auspices of the Company. As previously disclosed, the Board has curtailed spending on the Company's programs, including pre-clinical and clinical activities, until the review by the Business Review Committee and the Board is complete and the Board has determined the actions and plans to be implemented.
the Company will explore additional opportunities to create new paths toward shareholder value